Clinical investigation of fenoterol, a new bronchodilator, in asthma.
In a randomized, double-blind, noncrossover, study, 28 asthmatic patients received either ephedrine or fenoterol (Th1165a) a new beta 2-sympathomimetic bronchodilator, for 90 days. Forced expiratory flows and volumes and plethysmography were performed after a single test dose on days 1, 45, and 90. The subjects' clinical course was followed for patient acceptance and side effects. Compared to ephedrine, Th1165a was demonstrated to be a potent bronchodilator with a prolonged duration of action. Adrenergic side effects were minimal, and no tolerance or toxicity was demonstrated.
D001249:Asthma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004809:Ephedrine / Q000627:therapeutic use*; D004983:Ethanolamines / Q000627:therapeutic use*; D005280:Fenoterol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D012129:Respiratory Function Tests; D013997:Time Factors
D004983:Ethanolamines; D005280:Fenoterol; D004809:Ephedrine